raf@ A thought - maybe not bright - but still A Thought :)
Knowing that it's actually Teva - selling Lovaza - you could look at that as a blockage for making a Partner deal with Teva for Vascepa. -------------------------
But if you turn it around - Teva is 'exactly the right partner for this. Instead of 'fighting Amarin' - loosing Lovaza marked all the time, Teva can go out into the world and announce:
"We now have the wunder drug that over the next months will replace Lovaza - and this drug will be on of the biggest and most important drugs for humanity ever - with potential to save hundreds of millions of CDV patients Worldwide". --------------------------
Idea: Teva would have 'both groups of customers' from the start. And they could just 'nice and easy' transfer earlier Lovaza patients to Vascepa - in the tempo where logistics and production would be able to handle it.
Teva would benefit - sky would be the limit for expansion of new Vascepa customers WW. CDV patient all over planet earth would benefit - a total WIN - WIN :)